50 related articles for article (PubMed ID: 17577775)
1. Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution.
Aoki H; Ogura R; Tsukamoto Y; Okada M; Natsumeda M; Isogawa M; Yoshida S; Fujii Y
Neurol Med Chir (Tokyo); 2013; 53(11):797-804. PubMed ID: 24162244
[TBL] [Abstract][Full Text] [Related]
2. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
[TBL] [Abstract][Full Text] [Related]
3. The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study.
Zhang Y; Wang W; Zhao D; Chong W; Chen C; Zhang W; Zhou D
Cancer Med; 2024 May; 13(9):e7193. PubMed ID: 38738459
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.
Welch MR; Omuro A; Deangelis LM
Neuro Oncol; 2012 Oct; 14(10):1304-11. PubMed ID: 22952196
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of 15 cases of primary non-immunodeficient central nervous system lymphoma in children].
Gao HX; Zhang NN; Zhou CJ; Jin L; Yang J; Huang S; Zhang M; Li N; Zhang YH; Duan YL
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):190-194. PubMed ID: 38604797
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in treatment of primary central nervous system lymphoma.
Nayak L; Batchelor TT
Curr Treat Options Oncol; 2013 Dec; 14(4):539-52. PubMed ID: 23934511
[TBL] [Abstract][Full Text] [Related]
7. Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
Burnette BL; Jentoft MA; Porrata LF; Boyce TG; Witzig TE
J Clin Oncol; 2014 Mar; 32(7):e14-7. PubMed ID: 24395859
[No Abstract] [Full Text] [Related]
8. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors.
Bayraktar S; Bayraktar UD; Ramos JC; Stefanovic A; Lossos IS
J Neurooncol; 2011 Jan; 101(2):257-65. PubMed ID: 20526793
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
10. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
[TBL] [Abstract][Full Text] [Related]
12. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
13. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
14. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher RI; DeVita VT; Hubbard SM; Longo DL; Wesley R; Chabner BA; Young RC
Ann Intern Med; 1983 Mar; 98(3):304-9. PubMed ID: 6600902
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
